Table 2.
Antimicrobial susceptibility of Kluyvera cryocrescens in clinical isolates from bacteremic cases.
| No. 1 | No. 2–5 | No. 6 | No. 7 | No. 8 | No. 9 | Susceptibility | |
|---|---|---|---|---|---|---|---|
| Ampicillin | R | R | R | R | 0.0% | ||
| Amoxicillin/clavlulanate | S | I | S | 66.7% | |||
| Piperacillin/tazobactam | S | R | S | 66.7% | |||
| 1st gen cepahlospoins (ex: cefazolin) | R | R | S | 33.3% | |||
| 2nd gen cephem (ex: cefotiam) | R | R | S | 33.3% | |||
| 3rd gen cephem (ex: ceftriaxone) | R | S | S/I | S | 60.0% | ||
| 4th gen cephem (ex: cefepime) | S | S | 100.0% | ||||
| Imipenem | S | S | S | S | 100.0% | ||
| Amikacin | R | S | S | S | 75.0% | ||
| Gentamicin | S | S | R | S | 75.0% | ||
| Ciprofloxacin | S | S | S | S | S | 100.0% | |
| Doxycycline | S | S | 100.0% |
S, sensitive; R, resistant; ex, example.